表紙
市場調査レポート

Hetero Drugs Limitedの製品パイプライン分析

Hetero Drugs Limited - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321959
出版日 ページ情報 英文 23 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Hetero Drugs Limitedの製品パイプライン分析 Hetero Drugs Limited - Product Pipeline Review - 2015
出版日: 2015年12月30日 ページ情報: 英文 23 Pages
概要

Hetero Drugs Limitedはインドに本社を置く研究を基礎としたファーマシューティカル企業です。API、化学中間体、最終製剤などの研究開発、製造、販売を行っています。同社はバイオジェネリクス医薬品の製造開発に特化しており、カスタムされた研究および製造サービスを世界のバイオテクノロジー企業・ファーマシューティカル企業に提供しています。

当レポートでは、Hetero Drugs Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Hetero Drugs Limitedの基本情報

  • Hetero Drugs Limitedの概要
  • 主要情報
  • 企業情報

Hetero Drugs Limited:R&Dの概要

  • 主な治療範囲

Hetero Drugs Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Hetero Drugs Limited:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 創薬中の製品/併用療法モダリティ

Hetero Drugs Limited:薬剤プロファイル

  • rituximab biosimilar
  • Small Molecules for Diabetes
  • Small Molecules for Hepatitis C
  • Small Molecules for HIV

Hetero Drugs Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Hetero Drugs Limited:休止中のプロジェクト

Hetero Drugs Limited:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07934CDB

Summary

Global Markets Direct's, 'Hetero Drugs Limited - Product Pipeline Review - 2015', provides an overview of the Hetero Drugs Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Hetero Drugs Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Hetero Drugs Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Hetero Drugs Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Hetero Drugs Limited's pipeline products

Reasons to buy

  • Evaluate Hetero Drugs Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Hetero Drugs Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Hetero Drugs Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Hetero Drugs Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hetero Drugs Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Hetero Drugs Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Hetero Drugs Limited Snapshot
    • Hetero Drugs Limited Overview
    • Key Information
    • Key Facts
  • Hetero Drugs Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Hetero Drugs Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Hetero Drugs Limited - Pipeline Products Glance
    • Hetero Drugs Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Hetero Drugs Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Hetero Drugs Limited - Drug Profiles
    • adalimumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • trastuzumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hetero Drugs Limited - Pipeline Analysis
  • Hetero Drugs Limited - Pipeline Products by Target
  • Hetero Drugs Limited - Pipeline Products by Route of Administration
  • Hetero Drugs Limited - Pipeline Products by Molecule Type
  • Hetero Drugs Limited - Pipeline Products by Mechanism of Action
  • Hetero Drugs Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hetero Drugs Limited, Key Information
  • Hetero Drugs Limited, Key Facts
  • Hetero Drugs Limited - Pipeline by Indication, 2015
  • Hetero Drugs Limited - Pipeline by Stage of Development, 2015
  • Hetero Drugs Limited - Monotherapy Products in Pipeline, 2015
  • Hetero Drugs Limited - Partnered Products in Pipeline, 2015
  • Hetero Drugs Limited - Partnered Products/ Combination Treatment Modalities, 2015
  • Hetero Drugs Limited - Phase III, 2015
  • Hetero Drugs Limited - Preclinical, 2015
  • Hetero Drugs Limited - Pipeline by Target, 2015
  • Hetero Drugs Limited - Pipeline by Route of Administration, 2015
  • Hetero Drugs Limited - Pipeline by Molecule Type, 2015
  • Hetero Drugs Limited - Pipeline Products by Mechanism of Action, 2015
  • Hetero Drugs Limited, Other Locations
  • Hetero Drugs Limited, Subsidiaries

List of Figures

  • Hetero Drugs Limited - Pipeline by Top 10 Indication, 2015
  • Hetero Drugs Limited - Pipeline by Stage of Development, 2015
  • Hetero Drugs Limited - Monotherapy Products in Pipeline, 2015
  • Hetero Drugs Limited - Pipeline by Top 10 Target, 2015
  • Hetero Drugs Limited - Pipeline by Top 10 Route of Administration, 2015
  • Hetero Drugs Limited - Pipeline by Top 10 Molecule Type, 2015
  • Hetero Drugs Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top